adenyl cyclase Inhibitors
1 drugsAbout adenyl cyclase
Adenylyl cyclase is an enzyme that catalyzes the synthesis of cyclic AMP (cAMP) from ATP, a crucial second messenger regulating numerous physiological processes.
Adenylyl cyclase is a drug target in respiratory diseases, but there is currently no genetic evidence data available linking it to specific diseases.
There is one FDA-approved drug, SEREVENT (GSK), a small molecule targeting adenyl cyclase for respiratory indications since 1994.
Top adenyl cyclase Drugs
GSK is the only company with an approved drug targeting adenyl cyclase.
Low market concentration indicates a potential opportunity for new entrants in this therapeutic area.
adenyl cyclase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets adenyl cyclase, using small molecule modality.
The lack of modality diversity suggests a whitespace opportunity for novel biologics targeting adenyl cyclase.
adenyl cyclase Clinical Trials 47 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on adenyl cyclase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 11 | 10 | 1 | 0 | 91% |
| Phase 2 | 8 | 8 | 0 | 0 | 100% |
| Phase 3 | 13 | 10 | 2 | 1 | 83% |
| Phase 4 | 15 | 14 | 1 | 0 | 93% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
adenyl cyclase Drug Approval Timeline (1994 - 1994)
The first and only drug, SEREVENT, was approved in 1994.
The lack of recent approvals suggests potential saturation or renewed opportunity for innovation in adenyl cyclase targeting.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 22 (14 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on adenyl cyclase. A trial counts if an approved drug acting on adenyl cyclase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.